Biocon Limited Q1 FY27 Earnings Conference Call Summary

Financial Performance Highlights

Group Performance Q1 FY27:

  • Operating revenue grew 10% year-on-year
  • EBITDA reached INR902 crores with 21% margin
  • Interest cost declined 23% YoY and 8% QoQ to INR213 crores
  • Reported net profit before exceptionals was INR145 crores, representing 245% YoY increase

Segment-wise Performance:

Biosimilars Business:

  • Revenue: INR2,855 crores (16% YoY growth)
  • EBITDA: INR728 crores (10% YoY growth)
  • EBITDA Margin: 25%
  • R&D Investment: 7% of revenues

Generics Business:

  • Revenue: INR760 crores (21% YoY growth)
  • EBITDA: INR56 crores
  • EBITDA Margin: 7% (improved more than 250 basis points over Q4FY26)
  • API to formulations split: 60:40

Services Business (Syngene International):

  • Revenue: INR736 crores (16% YoY decline)
  • Operating EBITDA Margin: 12%

Key Business Updates and Developments

Manufacturing Milestones:

  • Received EMA approval for second drug product line at Malaysia insulin facility
  • Supplies from new line started in Q1 with expected pickup from Q2 FY27

Product Launches and Expansion:

  • Launched denosumab biosimilar (Aukelso™) across multiple European markets
  • Launched bevacizumab biosimilar (Abevmy™) in Czech Republic and Switzerland
  • Launched Yesafili™ (biosimilar aflibercept) in Malaysia - first approved biosimilar aflibercept in the country
  • Expanded commercial footprint through strategic partnerships in France, Portugal, Slovenia, and Spain

Strategic Initiatives:

  • Syngene entered strategic collaboration with BRIC-THSTI (Department of Biotechnology, Government of India)
  • Continued strengthening of SynAI, Syngene's AI-enabled drug discovery platform
  • Focus on cost optimization and operational efficiency across all businesses

Management Guidance and Outlook

Full Year FY27 Expectations:

  • Syngene expected to show single-digit revenue degrowth in rupee terms for full year
  • Syngene EBITDA margins expected to return to mid-20s
  • Biosimilars momentum expected to build progressively through the year with meaningful acceleration in second half
  • Generics new launches expected to scale up in subsequent quarters

Growth Drivers:

  • Five key products identified for growth: Aflibercept, Denosumab, Insulin Aspart, Ustekinumab, and Bevacizumab
  • July-September identified as key window for payor negotiations for following calendar year
  • Expectation of one new product launch annually in US or Europe through end of decade

Capital Structure and Debt Management

Debt and Working Capital:

  • Net debt increased by approximately INR1,100 crores sequentially
  • Working capital increase due to higher inventory and receivables in preparation for second-half scale-up
  • Days of inventory outstanding normalized to 280-290 from previous 400+ days
  • Continued focus on debt reduction with free cash flow prioritized for debt repayment

Geographic Market Performance

North America:

  • Largest and most strategically important market
  • Policy environment favorable for biosimilars with focus on affordability and access
  • Recent launches include Bosaya™, Aukelso™ (denosumab), Yesafili™ (aflibercept), and liraglutide
  • Insulin glargine market shares growing steadily

Europe:

  • Combined portfolio of 11 biosimilars and 8 generic medicines
  • Focus on tailored commercial strategies across retail and tender channels

Emerging Markets:

  • Important growth opportunity driven by increasing healthcare access
  • Broader portfolio following business integration
  • Regional supply networks strengthened through local partnerships and contract manufacturing

Risk Factors and Challenges

Syngene Performance:

  • Impacted by lower offtake from key biologics client
  • Forex hedge loss incurred during quarter
  • FY27 characterized as transition year

Competitive Environment:

  • Price erosion acknowledged as real market dynamic
  • Focus on maintaining profitability while growing market share

Regulatory Environment:

  • Mention of potential US tariff concerns under Trump administration, though current law exempts generics and biosimilars
  • Active participation in policy discussions through industry forums

Participants in Earnings Call

Biocon Management: Dr. Kiran Mazumdar Shaw (Executive Chairperson), Mr. Shreehas Tambe (CEO & MD), Mr. Kedar Upadhye (CFO), Mr. Anuj Goel (CDO), Mr. Matthew Erick (CCO - Advanced Markets), Ms. Rhonda Duffy (COO), Mr. Susheel Umesh (CCO - Emerging Markets), Mr. Amit Kaptain (Head - Global API Commercials), Mr. Prashant Nair (Head Investor Relations)

Syngene Management: Mr. Siddharth Mittal (CEO & MD), Mr. Deepak Jain (CFO)

External Analysts: Representatives from CWC Advisors, Bank of America, Phillip Capital, Goldman Sachs, HSBC, Canara Robeco AMC, and individual investors

Additional Information

  • Call included forward-looking statements subject to risks and uncertainties
  • Focus remains on improving free cash flow generation, reducing leverage, and driving sustained improvement in return ratios